Immunome Q1 net loss widens to $53.8 million as collaboration revenue falls to zero
Immunome reported first-quarter 2026 results with no collaboration revenue, compared with $2.9 million a year earlier. Its net loss widened to $53.8 million from $41.6 million as research and development and general and administrative costs rose. The company said it submitted a New Drug Application for varegacestat to the FDA in April 2026 and expects its $582.7 million in cash to fund operations into 2028.
Key points
- Net loss was $53.8 million for the quarter ended March 31, 2026, versus $41.6 million a year earlier.
- Collaboration revenue was $0 versus $2.9 million in the first quarter of 2025.
- Research and development expenses were $46.4 million, up from $36.9 million; general and administrative expenses were $13.0 million, up from $10.7 million.
- Net loss per share was $0.48, compared with $0.52, on 113,136,836 weighted-average shares versus 79,410,354 a year earlier.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.